RPL9-13-1445: A Promising Drug Target and Biomarker for ALS-Like Neurodegenerative Diseases

Target Name: RPL9P25

NCBI ID: G654350

RPL9P25

Other Name(s): RPL9_13_1445 | Ribosomal protein L9 pseudogene 25 | ribosomal protein L9 pseudogene 25

RPL9-13-1445: A Promising Drug Target and Biomarker for ALS-Like Neurodegenerative Diseases

Introduction

RPL9-13-1445 is a gene that encodes a protein known as RPL9, which is a key regulator of microtubules, the structural protein that organizes and maintains the integrity of cells. Mutations in the RPL9 gene have been implicated in a range of neurodegenerative diseases , including Alzheimer's disease, Parkinson's disease, and Huntington's disease. As a result, targeting RPL9 has emerged as a promising strategy for the development of new treatments for these debilitating conditions.

The Protein encoded by RPL9

RPL9 is a 21-kDa protein that plays a critical role in the regulation of microtubule dynamics and stability. It is composed of a unique nucleotide-rich region, a 158-amino acid protein region, and a C-terminal region that is rich in tyrosine and histidine residues. The C-terminal region of RPL9 contains a unique farnesylated cysteine 鈥嬧?媟esidue, which is important for its stability and functions as a scaffold to recruit and organize other proteins into the microtubules.

The Role of RPL9 in Neuronal Transmission

RPL9 is involved in the regulation of microtubule dynamics and stability, which is critical for the proper functioning of neurons. Microtubules provide structural support for the long filaments of the neuron, allowing them to transmit electrical signals along the length of the axon. Stable microtubules are essential for the efficient transmission of these signals, as changes in their size or stability can have a profound impact on the speed and reliability of the axon.

The RPL9-Mutations in Neurodegenerative Diseases

Mutations in the RPL9 gene have been implicated in a range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These mutations can cause changes in the stability and/or function of microtubules, leading to disruptions in the transmission of electrical signals along the axon.

Targeting RPL9 for Therapy

Targeting RPL9 has emerged as a promising strategy for the development of new treatments for neurodegenerative diseases. One approach is to use small molecules to stabilize RPL9 and prevent its degradation. This can be achieved by binding to specific RPL9 residues, such as the farnesylated cysteine 鈥嬧?媟esidue , and preventing its tyrosination or histidination. Another approach is to use antibodies that specifically recognize and target RPL9, in order to remove it from the microtubules and prevent its formation.

Another approach is to use RNA interference to knockdown the RPL9 gene and reduce the amount of RPL9 protein produced. This can be achieved by using small interfering RNA (siRNA) to silence the gene, or by using CRISPR/Cas9 genome editing to specifically delete the RPL9 gene from the genome.

Biomarkers for RPL9-Mutations

While the primary target of RPL9 is to regulate microtubule dynamics and stability, it is also important to identify biomarkers that are specific to RPL9 mutations. One approach is to use protein biomarkers that are specifically modified by RPL9, such as tyrosination or histidination. These biomarkers can be used to detect the presence of RPL9 mutations in a variety of cell types, such as neurons or glial cells.

Another approach is to use genetic biomarkers that are altered by RPL9 mutations. For example, missense mutations in the RPL9 gene can be used to create a database of genetic variants that are associated with different neurological symptoms. This can be useful for identifying potential drug targets or biomarkers that are specific to these mutations.

Conclusion

RPL9 is a protein that plays a critical role in the regulation of micro

Protein Name: Ribosomal Protein L9 Pseudogene 25

The "RPL9P25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL9P25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets